ID | 1083 |
Name of the vaccine | Hexaxim |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | From 6 weeks |
Description of the vaccine | DTaP-HepB-IPV-Hib fully liquid hexavalent vaccine. |
Name of the manufacturer | Sanofi Pasteur |
Name of the manufacturing country | France |
Year of manufacture | 2012 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | 93 and 100% of the children had protective antibodies levels. |
Vaccine formulation | Whitish, cloudy suspension |
Dosage | Primary vaccination: Three doses of 0.5 ml and booster dose during the second year. |
Mechanism of action | Make antibodies and the active substances are fixed onto aluminium compounds. |
Route of administration | Intramuscular |
Indications | Primary and booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. |
Export | NA |
Approval | WHO |
Adjuvant | Aluminium hydroxide |
Repurposing | For diphtheria, Hib, pertussis, hepatitis B, poliomyelitis. |
Side effects of vaccine | Pain and redness at the injection site, irritability and crying. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT02428491 |
Reference | https://www.who.int/immunization_standards/vaccine_quality/pq_284_Hexaxim_1dose_SP_Hexaxim_VPSAR.pdf |
Other name | NA |
Additional Links | https://www.ema.europa.eu/en/documents/outside-eu-summary/hexaxim-medicine-overview_en.pdf
|